High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer

Eliahu Ge Z*, Susan Goodman, Rut Isaeson, Cilla Gerra, Aaron Sulkes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Most of the patients received the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2×2 mg. kg and 2×0-2 mg/kg, respectively. In 41% of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: Drowsiness, restlessness and diarrhea. HD-MCP and DXM are recommended in modified dose for preventing CMF chemotherapy induced emesis.

Original languageEnglish
Pages (from-to)173-175
Number of pages3
JournalOncology
Volume43
Issue number3
DOIs
StatePublished - 1986
Externally publishedYes

Keywords

  • 5-Fluorouracil
  • Antiemetic
  • CMF chemotherapy
  • Cyclophosphamide
  • Dexamethasone
  • Methotrexate
  • Metoclopramide

Fingerprint

Dive into the research topics of 'High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer'. Together they form a unique fingerprint.

Cite this